EGFR-Non-Small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market...
Thelansis’s "EGFR-Non-Small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential EGFR-Non-Small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
EGFR-mutated non-small cell lung cancer (NSCLC) is a molecular subtype in which activating changes in the EGFR gene drive tumor growth. Symptoms may include cough, breathlessness, chest pain, or problems caused by metastases; brain involvement is important. Diagnosis relies on molecular testing of tumor tissue and/or blood, noting that a negative plasma test may not exclude a mutation. For advanced disease with common exon 19 deletions or exon 21 L858R mutations, options include osimertinib alone, osimertinib with platinum-pemetrexed, or amivantamab plus lazertinib. Exon 20 insertions and less common variants require different treatment choices. Although targeted therapy can control disease, resistance may develop through additional EGFR changes, bypass signaling, or tumor transformation. Repeat molecular testing at progression can guide subsequent therapy. Research is evaluating bispecific antibodies, antibody-drug conjugates, and rational combinations to extend disease control.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest EGFR-Non-Small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the EGFR-Non-Small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.